Unknown

Dataset Information

0

Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells.


ABSTRACT: A substantial number of ductal carcinoma in situ (DCIS) detected by mammography never progress to invasive ductal carcinoma (IDC) and current approaches fail to identify low-risk patients not at need of adjuvant therapies. We aimed to identify the key miRNAs protecting DCIS from malignant evolution, that may constitute markers for non-invasive lesions. We studied 100 archived DCIS samples, including pure DCIS, DCIS with adjacent IDC and pure DCIS from patients with subsequent IDC in contralateral breast or no recurrence. A DCIS derived cell line was used for molecular and cellular studies. A genome wide study revealed that pure DCIS has higher miR-126 and miR-218 expression than DCIS with adjacent IDC lesions or than IDC. The down-regulation of miR-126 and miR-218 promoted invasiveness in vitro and, in patients with pure DCIS, was associated with later onset of IDC. Survival studies of independent cohorts indicated that both miRNAs play a protective role in IDC. The clinical findings are in agreement with the miRNAs' roles in cell adhesion, differentiation and proliferation. We propose that miR-126 and miR-218 have a protective role in DCIS and represent novel biomarkers for the risk assessment in women with early detection of breast cancer.

SUBMITTER: Volinia S 

PROVIDER: S-EPMC5955110 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6548759 | BioStudies
2019-01-01 | S-EPMC6616329 | BioStudies
2018-01-01 | S-EPMC6113263 | BioStudies
| S-EPMC6736745 | BioStudies
| S-ECPF-GEOD-26304 | BioStudies
| S-ECPF-GEOD-66301 | BioStudies
2014-01-01 | S-EPMC4076240 | BioStudies
1000-01-01 | S-EPMC2695476 | BioStudies
1000-01-01 | S-EPMC4480702 | BioStudies
| S-ECPF-GEOD-3893 | BioStudies